Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 4(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05058040Phase 4Active Not Recruiting

A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

Role: lead

NCT05181475Phase 4Active Not Recruiting

Long-term Efficacy and Safety Study of GV-971

Role: lead

NCT05908695Phase 4Recruiting

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Role: lead

NCT04520412Phase 3Suspended

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

Role: lead

All 4 trials loaded